AGTC to Participate in Upcoming Investor Conferences
March 08 2022 - 4:05PM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
clinical stage biotechnology company focused on the development and
commercialization of adeno-associated virus (AAV)-based gene
therapies for the treatment of rare and debilitating diseases with
an initial focus on inherited retinal diseases (IRDs), today
announced that management will be participating in the following
virtual investor conferences:
-
34th Annual ROTH
Conference (March 13 - 15, 2022)A presentation by Jon
Lieber, Chief Financial Officer, is now available to view
on-demand.
- Cantor Fitzgerald Virtual
Rare Orphan Disease Summit (March 29, 2022)Sue Washer,
President and Chief Executive Officer, will be participating in a
panel discussion entitled “Gene Therapy Pioneers: Why Experience
Matters When Targeting Rare Diseases.” The panel discussion will
begin at 4:00 p.m. ET.
- H.C. Wainwright Gene
Therapy and Gene Editing Conference (March 30, 2022)A
fireside chat with Ms. Washer will be available to view on-demand
beginning at 7:00 a.m. ET.
Audio webcasts of the presentations and panel
discussion can be accessed by visiting
http://ir.agtc.com/events-and-presentations. Replays will be
available on the Company's website following the events.
About AGTCAGTC is a
clinical-stage biotechnology company developing genetic therapies
for people with rare and debilitating ophthalmic, otologic and
central nervous system (CNS) diseases. AGTC is a leader in
designing and constructing all critical gene therapy elements and
bringing them together to develop customized therapies with the
potential to address unmet patient needs. AGTC’s most advanced
clinical programs in X-linked retinitis pigmentosa (XLRP) and
achromatopsia (ACHM CNGB3) leverage its best-in-class technology
platform to potentially improve vision for patients with inherited
retinal diseases. Its preclinical programs build on the Company’s
industry leading AAV manufacturing technology and scientific
expertise. AGTC is advancing multiple important pipeline candidates
to address substantial unmet clinical need in optogenetics, otology
and CNS disorders, and has entered into strategic collaborations
with companies including Bionic Sight, an innovator in the emerging
field of optogenetics and retinal coding and Otonomy, Inc., a
biopharmaceutical company dedicated to the development of
innovative therapeutics for neurotology. For more information,
please visit https://agtc.com/.
IR Contact: David
CareyLazar FINN PartnersT: (212)
867-1768david.carey@finnpartners.com
Corporate Contact:Jonathan
LieberChief Financial OfficerApplied Genetic Technologies
CorporationT: (617) 843-5778jlieber@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Sep 2023 to Sep 2024